Filing summary
Entity and period: The supplied filing is AcelRx Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2012—not a filing identified as Talphera, Inc. The company was a development-stage specialty pharmaceutical business developing treatments for acute and breakthrough pain. Financial amounts below are in millions of dollars unless noted.
Financial and operating results
- Revenue: No product-sales revenue. U.S. Army research-grant revenue was $0.166 million for Q3 2012 and $0.719 million for the first nine months of 2012, versus $0.408 million and $0.448 million, respectively, in 2011.
- Expenses and loss: Q3 research and development expense was $6.948 million, up 76% year over year; general and administrative expense was $1.410 million, down 24%. Net loss was $8.582 million, or $0.38 per share, versus $5.761 million, or $0.30 per share, in Q3 2011. For the first nine months, R&D expense was $17.113 million, up 92%; G&A was $5.290 million, up 4%; and net loss was $22.841 million, or $1.09 per share, versus $13.729 million, or $0.83 per share.
- Cash flow: Operating cash use was $18.783 million for the first nine months of 2012, compared with $9.296 million in 2011. Investing activities provided $7.276 million, primarily from investment maturities; financing provided $7.434 million, chiefly net proceeds of $9.077 million from the June private placement, offset in part by debt repayments.
- Liquidity: At September 30, cash, cash equivalents and short-term investments totaled $23.375 million, down from $35.785 million at December 31, 2011. Working capital was $13.1 million. Management said available cash and investments were expected to fund planned operations into Q2 2013.
- Debt and balance sheet: Hercules debt had an 8.5% interest rate and a December 2014 scheduled maturity; principal-and-interest installments began in July 2012. The balance sheet reported $7.226 million of current debt and $10.456 million of long-term debt, net of discounts. The notes report $17.7 million of outstanding borrowings net of discounts; elsewhere, the risk discussion states $18.2 million of principal outstanding. Total liabilities were $28.478 million, and stockholders’ equity was negative $0.327 million.
- Margins: Product-sales margins are not applicable because the company had not begun commercial sales. The filing does not present a meaningful commercial gross margin.
Material changes and developments
- R&D spending rose mainly because all three ARX-01 Phase 3 trials began in 2012; nine-month ARX-01 spending increased to $12.354 million from $4.942 million.
- In June, the company raised $10.0 million gross through a private placement of common shares and warrants, receiving $9.1 million net. The warrants were recorded as a liability; their estimated fair value was $5.345 million at quarter-end.
- An at-the-market sales agreement signed in August allowed up to the lesser of the Form S-3 permitted amount or $7.5 million in share sales. No shares had been sold under it by September 30.
- Cash and investments fell by $12.410 million from year-end 2011, while accumulated deficit increased to $111.5 million from $88.7 million.
Outlook, commentary and risks
- The company had completed enrollment in its ARX-01 Phase 3 comparison with IV PCA morphine and expected top-line results in November 2012; results from two other Phase 3 trials were expected in Q1 2013. It stated a goal, conditional on financing and successful trials, of submitting an ARX-01 NDA in Q3 2013.
- After the reporting date, in November 2012, the company said it initiated an ARX-04 Phase 2 trial following USAMRMC approval. The $5.6 million grant period had been extended through May 31, 2013; further ARX-04 development funding was uncertain.
- Management expected R&D expense and cash use to increase as clinical programs advanced. Additional capital or collaborations would be needed for future operations. If funding proved unavailable, the company might curtail activities, including the final planned ARX-01 Phase 3 trial.
- Key risks included clinical-trial failure or delay, FDA and drug-device combination approval uncertainty, dependence on limited third-party manufacturing and controlled-substance supply, grant-funding uncertainty, and the need to raise capital. New equity could dilute shareholders; debt could add obligations and restrictions. Hercules held a security interest in substantially all assets other than intellectual property, subject to the stated limitations.
- The company reported no material pending litigation, no off-balance-sheet arrangements, and effective disclosure controls. No material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the issuer: this source identifies AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Check subsequent ARX-01 trial results, FDA interactions, completion of required studies, and whether the stated NDA timing was achieved.
- Assess actual cash burn and financing after September 30, 2012 against the stated Q2 2013 runway, including any ATM issuance or partnership funding.
- Reconcile debt disclosures: balance-sheet carrying value, $17.7 million net borrowings, and $18.2 million principal stated in the risk discussion.
- Review the terms, exercise and dilution implications of the private-placement warrants and the resulting warrant-liability remeasurement.
- Verify the continuation and sufficiency of USAMRMC funding and manufacturing, supply, and regulatory readiness for the clinical programs.